|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marioni G, Marchese-Ragona R, Cartei G,
Marchese F and Staffieri A: Current opinion in diagnosis and
treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alhamarneh O, Amarnath SM, Stafford ND and
Greenman J: Regulatory T cells: What role do they play in antitumor
immunity in patients with head and neck cancer? Head Neck.
30:251–261. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen B, Zhang D, Zhou J, Li Q, Zhou L, Li
SM, Zhu L, Chou KY, Zhou L, Tao L and Lu LM: High CCR6/CCR7
expression and Foxp3+ Treg cell number are positively
related to the progression of laryngeal squamous cell carcinoma.
Oncol Rep. 30:1380–1390. 2013.PubMed/NCBI
|
|
6
|
Sun W, Li WJ, Fu QL, Wu CY, Lin JZ, Zhu
XL, Hou WJ, Wei Y, Wen YH, Wang YJ and Wen WP: Functionally
distinct subsets of CD4+ regulatory T cells in patients
with laryngeal squamous cell carcinoma are indicative of immune
deregulation and disease progression. Oncol Rep. 33:354–362.
2015.PubMed/NCBI
|
|
7
|
Kobayashi N, Hiraoka N, Yamagami W, Ojima
H, Kanai Y, Kosuge T, Nakajima A and Hirohashi S: FOXP3+ regulatory
T cells affect the development and progression of
hepatocarcinogenesis. Clin Cancer Res. 13:902–911. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pretscher D, Distel LV, Grabenbauer GG,
Wittlinger M, Buettner M and Niedobitek G: Distribution of immune
cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in
metastatic lymph nodes are associated with favourable outcome in
patients with oro- and hypopharyngeal carcinoma. BMC Cancer.
9:2922009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Banchereau J, Pascual V and O'Garra A:
From IL-2 to IL-37: The expanding spectrum of anti-inflammatory
cytokines. Nat Immunol. 13:925–931. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Collison LW, Workman CJ, Kuo TT, Boyd K,
Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS and Vignali DA:
The inhibitory cytokine IL-35 contributes to regulatory T-cell
function. Nature. 450:566–569. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Collison LW, Chaturvedi V, Henderson AL,
Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ,
Brown SA, et al: IL-35-mediated induction of a potent regulatory T
cell population. Nat Immunol. 11:1093–1101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Niedbala W, Wei XQ, Cai B, Hueber AJ,
Leung BP, McInnes IB and Liew FY: IL-35 is a novel cytokine with
therapeutic effects against collagen-induced arthritis through the
expansion of regulatory T cells and suppression of Th17 cells. Eur
J Immunol. 37:3021–3029. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y
and Wei XQ: IL-35 over-expression increases apoptosis sensitivity
and suppresses cell growth in human cancer cells. Biochem Biophys
Res Commun. 430:364–369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng JC, Zhang Z, Li TY, Liang YF, Wang
HM, Bao JJ, Zhang JA, Wang WD, Xiang WY, Kong B, et al: Assessing
the role of IL-35 in colorectal cancer progression and prognosis.
Int J Clin Exp Pathol. 6:1806–1816. 2013.PubMed/NCBI
|
|
15
|
Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu
J, Basu S, Feng Y and Bai XF: Tumor-derived IL-35 promotes tumor
growth by enhancing myeloid cell accumulation and angiogenesis. J
Immunol. 190:2415–2423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vignali DA and Kuchroo VK: IL-12 family
cytokines: Immunological playmakers. Nat Immunol. 13:722–728. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Collison LW, Delgoffe GM, Guy CS, Vignali
KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA,
Drake CG, et al: The composition and signaling of the IL-35
receptor are unconventional. Nat Immunol. 13:290–299. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsui M, Kishida T, Nakano H, Yoshimoto
K, Shin-Ya M, Shimada T, Nakai S, Imanishi J, Yoshimoto T, Hisa Y
and Mazda O: Interleukin-27 activates natural killer cells and
suppresses NK-resistant head and neck squamous cell carcinoma
through inducing antibody-dependent cellular cytotoxicity. Cancer
Res. 69:2523–2530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nicholl MB, Ledgewood CL, Chen X, Bai Q,
Qin C, Cook KM, Herrick EJ, Diaz-Arias A, Moore BJ and Fang Y:
IL-35 promotes pancreas cancer growth through enhancement of
proliferation and inhibition of apoptosis: Evidence for a role as
an autocrine growth factor. Cytokine. 70:126–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Sun H, Wu H, Tan Q and Xiang K:
Interleukin 35 is an independent prognostic factor and a
therapeutic target for nasopharyngeal carcinoma. Contemp Oncol
(Pozn). 19:120–124. 2015.PubMed/NCBI
|
|
22
|
Fan YG, Zhai JM, Wang W, Feng B, Yao GL,
An YH and Zeng C: IL-35 over-expression is associated with genesis
of gastric cancer. Asian Pac J Cancer Prev. 16:2845–2849. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Niedobitek G, Päzolt D, Teichmann M and
Devergne O: Frequent expression of the Epstein-Barr virus
(EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin
and Reed-Sternberg cells. J Pathol. 198:310–316. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wolf D, Wolf AM, Rumpold H, Fiegl H,
Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E and
Marth C: The expression of the regulatory T cell-specific forkhead
box transcription factor FoxP3 is associated with poor prognosis in
ovarian cancer. Clin Cancer Res. 11:8326–8331. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagaraj S and Gabrilovich DI: Tumor escape
mechanism governed by myeloid-derived suppressor cells. Cancer Res.
68:2561–2563. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hamidinia M, Boroujerdnia Ghafourian M,
Talaiezadeh A, Solgi G, Roshani R, Iranprast S and Khodadadi A:
Increased P-35, EBI3 transcripts and other treg markers in
peripheral blood mononuclear cells of breast cancer patients with
different clinical Stages. Adv Pharm Bull. 5:261–267. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gu X, Tian T, Zhang B, Liu Y, Yuan C, Shao
L, Guo Y and Fan K: Elevated plasma interleukin-35 levels predict
poor prognosis in patients with non-small cell lung cancer. Tumour
Biol. 36:2651–2656. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin P, Ren H, Sun W, Xin W, Zhang H and
Hao J: Circulating IL-35 in pancreatic ductal adenocarcinoma
patients. Hum Immunol. 75:29–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
